HIV News and Research

RSS

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

11 Oct 2009

Clinical trial reveals cholera vaccine is safe, offers protection for up to 2 years

A clinical trial of an Indian-made "modified killed-whole-cell" oral cholera vaccine "that meets WHO standards" has found that the vaccine is safe and effective in children living in parts of India where the disease is endemic, Reuters reports. The researchers, who reported their findings in the journal Lancet, hope to soon introduce the vaccine into other cholera endemic settings.

9 Oct 2009

Recent releases in Global Health

A Lancet comment examines an Affordable Medicines Facility for malaria (AMFm) program to help countries procure subsidized artemisinin-based combination treatments (ACTs).

9 Oct 2009

VOA News examines U.S. global health funding

VOA News examines how the recession will be a factor in U.S. funding decisions about PEPFAR and other global health initiatives. According to VOA, the Obama administration's proposed funding for HIV, tuberculosis and malaria in 2010 is "higher than the current fiscal year. However, the proposed increase is lower than in some years past."

9 Oct 2009

SCAA to host Survivor Celebration event to mark SCA Awareness Month

A nationwide gathering of sudden cardiac arrest (SCA) survivors will mark SCA Awareness Month with a Survivor Celebration on Friday, October 9th at 7 p.m. in Chicago. This survivor event, hosted by the Sudden Cardiac Arrest Association (SCAA) at the Hyatt Regency O’Hare, 9300 Bryn Mawr Avenue in Rosemont, is part of three-day program that will make up the organization’s annual meeting.

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

Millions of people with HIV/AIDS lack access to lifesaving treatment, says AHF

AIDS Healthcare Foundation (AHF) today hailed the news that four million people from low and middle income countries living with HIV/AIDS were on lifesaving antiretroviral treatment in 2008, a 36% increase over 2007.

9 Oct 2009

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

In response to new economic and regulatory realities, CytoDyn, Inc. has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS.

9 Oct 2009

AHF criticizes Pfizer for its current pricing of Selzentry AIDS drug

Responding to today’s news that the Food and Drug Administration (FDA) Antiviral Advisory Committee has approved Pfizer Inc.'s AIDS therapy, Selzentry (maraviroc), for use in therapy-naïve patients, AIDS Healthcare Foundation (AHF) strongly criticized Pfizer for its current pricing of the drug at an Average Wholesale Price (AWP) of $13,767 per-patient per-year—which, if this price remains when use is expanded, would make it the most expensive first-line AIDS drug on the market.

9 Oct 2009

Also in Global Health News: Uganda malaria efforts; child mortality in Vietnam; refugee health; U.S. aid to Somalia; HIV in South Africa

The Guardian examines efforts to reduce malaria in Katine, Uganda, through the distribution of insecticide-treated nets to high-risk groups. Though the article details a reduction in the number of malaria cases in the region, additional nets are needed to cover the entire population. Also, health experts warn additional strategies, such as indoor residual spraying and increased access to drugs are needed to defeat malaria (Kavuma, 10/8).

9 Oct 2009

Children's access to health care poses significant health problem despite of health insurance coverage

Despite high rates of health insurance coverage among children in the District of Columbia, children's access to health care is inadequate and poses a significant health problem for the city's young residents, particularly those who are publicly insured, according to a RAND Corporation study issued today.

9 Oct 2009

U.S. should provide more leadership in finding TB vaccine, opinion piece says

Tuberculosis deserves an effort as "substantial" as the one mounted against swine flu "to develop a new vaccine," David McMurray, a TB expert at Texas A&M University System Health Science Center, writes in a Houston Chronicle opinion piece.

9 Oct 2009

Journalists meet to discuss different aspects of biotechnology and its impact on society

More than 90 journalists from all over the world meet in Heidelberg, today, for the 4th Alumni Conference of the International Journalists’ Programmes (IJP). In keynote-speeches, panel discussions and excursions participants will discover different aspects of biotechnology and its impact on society.

8 Oct 2009

New research report outlines growth prospects of Biomagnetics Diagnostics

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company is the subject of a new research report issued by Emerging Growth Research, LLP.

8 Oct 2009

HTDS' Hepatitis A vaccine receives GMP Certificate from the Russian FDA

HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce that its Hepatitis A Live Attenuated Vaccine (Brand name: Mevac-A) associate operation plant has obtained the GMP Certificate (Good Manufacturing Practice See Description http://en.wikipedia.org/wiki/Good_manufacturing_practice) from the Russian FDA. http://www.who.int/hiv/HIVCP_RUS.pdf

8 Oct 2009

Needlestick injuries in home care nursing can also affect patients

Patients continue to enter home healthcare ''sicker and quicker," often with complex health problems that may require extensive nursing care. This increases the risk of needlestick injuries in home healthcare nurses.

8 Oct 2009

More than 2m infants, women die from childbirth annually, study says

Each year, more than 2 million infants and women around the world die from childbirth-related complications, according to a study released Tuesday at the International Federation of Gynecology and Obstetrics world congress in Cape Town, South Africa, the Associated Press reports.

8 Oct 2009

Also in Global Health News: Carter promotes malaria eradication; India to educate tribal populations about HIV/AIDS; WFP feels impact of global recession

Former President Jimmy Carter is traveling to Haiti and the Dominican Republic in hopes of encouraging the country "leaders to forge a pact to rid the island of Hispaniola of malaria," the Associated Press/Los Angeles Times reports.

8 Oct 2009

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization.

7 Oct 2009

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

7 Oct 2009